Selenium in cancer prevention: a review of the evidence and mechanism of action
Rayman, MP (2005) Selenium in cancer prevention: a review of the evidence and mechanism of action P NUTR SOC, 64 (4). 527 - 542. ISSN 0029-6651
|PDF - Published Version|
Official URL: http://journals.cambridge.org/action/displayAbstra...
Se is an unusual trace element in having its own codon in mRNA that specifies its insertion into selenoproteins as selenocysteine (SeCys), by means of a mechanism requiring a large SeCysinsertion complex. This exacting insertion machinery for selenoprotein production has implications for the Se requirements for cancer prevention. If Se may protect against cancer, an adequate intake of Se is desirable. However, the level of intake in Europe and some parts of the world is not adequate for full expression of protective selenoproteins. The evidence for Se as a cancer preventive agent includes that from geographic, animal, prospective and intervention studies. Newly-published prospective studies on oesophageal, gastric-cardia and lung cancer have reinforced previous evidence, which is particularly strong for prostate cancer. Interventions with Se have shown benefit in reducing the risk of cancer incidence and mortality in all cancers combined, and specifically in liver, prostate, colo-rectal and lung cancers. The effect seems to be strongest in those individuals with the lowest Se status. As the level of Se that appears to be required for optimal effect is higher than that previously understood to be required to maximise the activity of selenoenzymes, the question has been raised as to whether selenoproteins are involved in the anti-cancer process. However, recent evidence showing an association between Se, reduction of DNA damage and oxidative stress together with data showing an effect of selenoprotein genotype on cancer risk implies that selenoproteins are indeed implicated. The likelihood of simultaneous and consecutive effects at different cancer stages still allows an important role for anti-cancer Se metabolites such as methyl selenol formed from g-glutamyl-selenomethyl-SeCys and selenomethyl-SeCys, components identified in certain plants and Se-enriched yeast that have anti-cancer effects. There is some evidence that Se may affect not only cancer risk but also progression and metastasis. Current primary and secondary prevention trials of Se are underway in the USA, including the Selenium and Vitamin E Cancer Prevention Trial (SELECT) relating to prostate cancer, although a large European trial is still desirable given the likelihood of a stronger effect in populations of lower Se status.
|Uncontrolled Keywords:||selenium, cancer, mechanism, selenomethyl-selenocysteine, selenoprotein single-nucleotide polymorphism, BASE-LINE CHARACTERISTICS, PROSTATE-CANCER, SERUM SELENIUM, SE-METHYLSELENOCYSTEINE, DIETARY SELENIUM, GLUTATHIONE-PEROXIDASE, SUBSEQUENT RISK, BREAST-CANCER, VITAMIN-E, IN-VITRO|
|Divisions:||Faculty of Health and Medical Sciences > Nutrition and Metabolism|
|Deposited By:||Melanie Hughes|
|Deposited On:||05 Nov 2010 14:03|
|Last Modified:||24 Jan 2013 09:09|
Repository Staff Only: item control page